Abbott Laboratories Hits New 52-Week Low at $92.67

Abbott Laboratories has reached a new 52-week low, trading at USD 92.67 as of April 21, 2026. This significant decline highlights the stock's performance over the past year, which has seen a decrease of 13.74%. In contrast, the S&P 500 has experienced a robust gain of 36.95% during the same period, underscoring the challenges faced by Abbott in the current market environment. The company operates within the Pharmaceuticals & Biotechnology industry and boasts a market capitalization of USD 214,677 million, categorizing it as a large-cap entity. Abbott's price-to-earnings (P/E) ratio stands at 32.00, reflecting its valuation in relation to earnings. Despite the recent price drop, the company maintains a low debt-to-equity ratio of 0.10, indicating a strong ability to manage its debt obligations. Abbott has reported positive results for the last three consecutive quarters, with operating cash flow reaching a high of USD 9,037 million. The company's return on capital employed (ROCE) is also noteworthy at 13.01%. As Abbott navigates these market dynamics, its financial metrics suggest a complex landscape for stakeholders.